PRESS RELEASE

Integer Holdings Corporation Provides Notice of Make-Whole Fundamental Change, Fundamental Change and Right to Convert to Holders of its 2.125% Convertible Senior Notes due 2028 and 1.875% Convertible Senior Notes due 2030 in Connection with Completed Merger

PLANO, Texas, November 17, 2026 (GLOBE NEWSWIRE) – Integer Holdings Corporation ("Integer" or the "Company"), a leading medical device contract development and manufacturing organization, today delivered notices (each, a "Notice" and together, the "Notices") to holders of its 2.125% Convertible Senior Notes due 2028 (the "2028 Notes") and its 1.875% Convertible Senior Notes due 2030 (the "2030 Notes" and, together with the 2028 Notes, the "Notes"), pursuant to the Indenture, dated as of February 3, 2023, governing the 2028 Notes, and the Indenture, dated as of March 18, 2025, governing the 2030 Notes (each, an "Indenture"), in each case between the Company and Wilmington Trust, National Association, as trustee (the "Trustee"), that a Make-Whole Fundamental Change and a Fundamental Change (each as defined in the applicable Indenture) occurred under each Indenture on November 17, 2026 (the "Effective Date").

On the Effective Date, the Company completed its previously announced merger (the "Merger") with Armstrong Bidco, Inc., a wholly owned subsidiary of Armstrong Parent, Inc. ("Parent"), pursuant to the Agreement and Plan of Merger, dated as of August 2, 2026. As a result of the Merger, the Company became a wholly owned subsidiary of Parent, and each outstanding share of the Company's common stock (other than certain excluded shares) was converted into the right to receive $127.00 in cash, without interest (the "Merger Consideration").

Notice of Make-Whole Fundamental Change Effective Date

Pursuant to each Indenture, holders may convert their Notes in connection with the Merger at any time from, and including, the Effective Date to, and including, the close of business (5:00 p.m., New York City time) on January 8, 2027, which is the thirty-fifth (35th) Trading Day immediately following the Effective Date (the "Conversion Period"). Holders whose Notice of Conversion is received by the conversion agent during the period from, and including, the Effective Date to, and including, 5:00 p.m., New York City time, on January 8, 2027 (the "Make-Whole Fundamental Change Period"), will be entitled to an increased Conversion Rate, as follows:

2028 Notes. The consideration due upon conversion during the Make-Whole Fundamental Change Period will be cash of approximately $1,491.08 per $1,000 principal amount of 2028 Notes, based on a Conversion Rate of 11.7408 (the Conversion Rate of 11.4681 in effect immediately prior to the Merger, plus 0.2727 Additional Shares), multiplied by $127.00. A holder whose Notice of Conversion is received after the Make-Whole Fundamental Change Period ends will receive cash of $1,456.45 per $1,000 principal amount of 2028 Notes.

2030 Notes. The consideration due upon conversion during the Make-Whole Fundamental Change Period will be cash of approximately $1,029.25 per $1,000 principal amount of 2030 Notes, based on a Conversion Rate of 8.1043 (the Conversion Rate of 6.6243 in effect immediately prior to the Merger, plus 1.4800 Additional Shares), multiplied by $127.00. A holder whose Notice of Conversion is received after the Make-Whole Fundamental Change Period ends will receive cash of $841.29 per $1,000 principal amount of 2030 Notes.

Upon the expiration of the Make-Whole Fundamental Change Period, the Conversion Rate for each series of Notes will automatically, without further notice, return to the Conversion Rate in effect immediately prior to the Merger. After the Conversion Period ends, the Notes will no longer be convertible solely on account of the Merger and will be convertible only under the circumstances and during the periods set forth in the applicable Indenture.

Notice of Fundamental Change; No Repurchase Right

Under Section 15.02(e) of each Indenture, the Company is not required to offer to repurchase, or to repurchase, the Notes in connection with the Merger, because the Merger is a Merger Event for which the Reference Property consists solely of cash in U.S. dollars, the cash amount into which the Notes became convertible immediately after the Merger equals or exceeds the maximum Fundamental Change Repurchase Price for each series, and the Company has timely delivered the required notice. Accordingly, holders do not have the right to require the Company to repurchase their Notes in connection with the Merger.

Holders of Notes should read the applicable Notice carefully, as it contains important information regarding the procedures and timing for the exercise of conversion rights. The Notices are available through The Depository Trust Company or by requesting a copy from Wilmington Trust, National Association, which is serving as the conversion agent, at:

Wilmington Trust, National Association
1310 Silas Deane Highway
Wethersfield, CT 06109
Attn: Integer Holdings Corporation Notes Administrator

None of the Company, Parent, their respective boards of directors or employees, or the Trustee has made or is making any representation or recommendation to any holder as to whether to convert or refrain from converting its Notes.

This press release is for informational purposes only and is not an offer to purchase, or a solicitation of an offer to sell, any securities, nor shall there be any purchase or sale of securities in any state or jurisdiction in which such offer, solicitation, purchase or sale would be unlawful.

About Integer®

Integer Holdings Corporation is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.

Contacts

Media Relations:
Misty Tippen
misty.tippen@integer.net
469-536-6702

Investor Relations:
Kristen Stewart
kristen.stewart@integer.net
551-337-3973